Effect of Renal Function on Gadolinium-Related Signal Increases on Unenhanced T1-Weighted Brain Magnetic Resonance Imaging

Investigative Radiology

Volumn 51, Issue 11, 2016, Pages 677-682

  Cao, Yan ^a   Zhang, Yang ^a,b   Shih, George ^a   Bohmart, Andrew ^a   Hecht, Elizabeth M ^c   Prince, Martin R ^a,c  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b SHANDONG UNIVERSITY   (China)

^c New York Presbyterian Columbia University Medical Center   (United States)

Author keywords

choroid plexus; dentate nucleus; gadolinium; globus pallidus; hemodialysis; MRI

Indexed keywords

GADOBENATE DIMEGLUMINE; GADODIAMIDE; GADOLINIUM PENTETATE MEGLUMINE; CONTRAST MEDIUM; GADOBENIC ACID; GADOLINIUM; GADOLINIUM PENTETATE; MEGLUMINE; ORGANOMETALLIC COMPOUND;

ADULT; ARTICLE; BRAIN NUCLEUS; CARDIOVASCULAR DISEASE; CHOROID PLEXUS; CLINICAL ARTICLE; CONTROLLED STUDY; DENTATE GYRUS; DENTATE NUCLEUS; ELECTRONIC MEDICAL RECORD; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; GASTROINTESTINAL SYMPTOM; GLOBUS PALLIDUS; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; INFECTION; KIDNEY FAILURE; KIDNEY FUNCTION; MALE; MEDICAL RECORD REVIEW; MENTAL DISEASE; METABOLIC DISORDER; MIDDLE AGED; MUSCULOSKELETAL DISEASE; NEUROIMAGING; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; RETROSPECTIVE STUDY; THALAMUS; UNSPECIFIED SIDE EFFECT; WHITE MATTER; AGED; ANALOGS AND DERIVATIVES; BRAIN; DIAGNOSTIC IMAGING; DRUG EFFECTS; FACTUAL DATABASE; KIDNEY; KIDNEY FAILURE, CHRONIC; PATHOPHYSIOLOGY; PROCEDURES; SIGNAL PROCESSING;

AGED; BRAIN; CONTRAST MEDIA; DATABASES, FACTUAL; FEMALE; GADOLINIUM; GADOLINIUM DTPA; HUMANS; KIDNEY; KIDNEY FAILURE, CHRONIC; MAGNETIC RESONANCE IMAGING; MALE; MEGLUMINE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; RENAL DIALYSIS; RETROSPECTIVE STUDIES; SIGNAL PROCESSING, COMPUTER-ASSISTED;

EID: 84973312269     PISSN: 00209996     EISSN: 15360210     Source Type: Journal    
DOI: 10.1097/RLI.0000000000000294     Document Type: Article

References (55)

1. Kanda T, Ishii K, Kawaguchi H, et al. High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weightedMRimages: relationshipwith increasing cumulative dose of a gadolinium-based contrast material. Radiology. 2014;270:834-841.
2. Errante Y, Cirimele V,Mallio CA, et al. Progressive increase of T1 signal intensity of the dentate nucleus on unenhanced magnetic resonance images is associated with cumulative doses of intravenously administered gadodiamide in patientswith normal renal function, suggesting dechelation. Invest Radiol. 2014;49:685-690.
3. Ramalho J, CastilloM, AlObaidyM, et al. High signal intensity in globus pallidus and dentate nucleus on unenhanced T1-weighted MR images: evaluation of two linear gadolinium-based contrast agents. Radiology. 2015;276:836-844.
4. Quattrocchi CC,Mallio CA, Errante Y, et al. Gadodiamide and dentate nucleus T1 hyperintensity in patients with meningioma evaluated by multiple follow-up contrast-enhanced magnetic resonance examinations with no systemic interval therapy. Invest Radiol. 2015;50:470-472.
5. Quattrocchi CC. High T1 signal intensity in dentate nucleus after multiple injections of linear gadolinium chelates. Radiology. 2015;276:616-617.
6. Adin ME, Kleinberg L, Vaidya D, et al. Hyperintense dentate nuclei on T1-weighted MRI: relation to repeat gadolinium administration. AJNR Am J Neuroradiol. 2015;36:1859-1865.
7. Weberling LD, Kieslich PJ, Kickingereder P, et al. Increased signal intensity in the dentate nucleus on unenhanced T1-weighted images after gadobenate dimeglumine administration. Invest Radiol. 2015;50:743-748.
8. Huckle JE, Altun E, JayM, et al. Gadolinium deposition in humans: when did we learn that gadolinium was deposited in vivo? Invest Radiol. 2016;51:236-240.
9. Kanda T, Fukusato T,Matsuda M, et al.Gadolinium-based contrast agent accumulates in the brain even in subjects without severe renal dysfunction: evaluation of autopsy brain specimens with inductively coupled plasma mass spectroscopy. Radiology. 2015;276:228-232.
10. McDonald RJ, McDonald JS, Kallmes DF, et al. Intracranial gadolinium deposition after contrast-enhanced MR imaging. Radiology. 2015;275:772-782.
11. Robert P, Violas X, Grand S, et al. Linear gadolinium-based contrast agents are associated with brain gadolinium retention in healthy rats. Invest Radiol. 2016;51: 73-82.
12. Jost G, Lenhard DC, Sieber MA, et al. Signal increase on unenhanced T1-weighted images in the rat brain after repeated, extended doses of gadoliniumbased contrast agents: comparison of linear andmacrocyclic agents. Invest Radiol. 2016;51:83-89.
13. Robert P, Lehericy S, Grand S, et al. T1-weighted hypersignal in the deep cerebellar nuclei after repeated administrations of gadolinium-based contrast agents in healthy rats difference between linear and macrocyclic agents. Invest Radiol. 2015;50:473-480.
14. RungeVM. Commentary on T1-weighted hypersignal in the deep cerebellar nuclei after repeated administrations of gadolinium-based contrast agents in healthy rats: difference between linear andmacrocyclic agents. Invest Radiol. 2015;50:481-482.
15. Joffe P, Thomsen HS, Meusel M. Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Acad Radiol. 1998;5:491-502.
16. Swartz RD, Crofford LJ, Phan SH, et al. Nephrogenic fibrosing dermopathy: a novel cutaneous fibrosing disorder in patients with renal failure. Am J Med. 2003;114:563-572.
17. Rydahl C, Thomsen HS,Marckmann P. High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadoliniumcontaining magnetic resonance contrast agent. Invest Radiol. 2008;43:141-144.
18. Hope TA, Herfkens RJ, Denianke KS, et al. Nephrogenic systemic fibrosis in patients with chronic kidney disease who received gadopentetate dimeglumine. Invest Radiol. 2009;44:135-139.
19. Omniscan [Package Insert]. Princeton, NJ: GE Healthcare Inc. 2014. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/022066s007, 020123s043lbl.pdf. Accessed March 29, 2016.
20. Magnevist [Package Insert]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc. 2014. Available at: http://labeling.bayerhealthcare.com/html/products/pi/Magnevist-PI.pdf. Accessed March 11, 2016.
21. Multihance [Package Insert]. Monroe Township, NJ: Bracco Diagnositc Inc 2013. Available at: http://imaging.bracco.com/sites/braccoimaging.com/files/technica-sheet-pdf/MultiHance%20Prescribing%20Information.pdf. Accessed March 11, 2016.
22. Optimark [Package Insert]. St Louis, MO: Mallinckrodt Inc. 2014. Available at: http://medlibrary.org/lib/rx/meds/optimark-1/page/5/. Accessed March 11, 2016.
23. Runge VM. Safety of the gadolinium-based contrast agents for magnetic resonance imaging, focusing in part on their accumulation in the brain and especially the dentate nucleus. Invest Radiol. 2016;51:273-279.
24. Kanda T, Oba H, Toyoda K. Recent advances in understanding gadolinium retention in the brain. AJNR Am J Neuroradiol. 2016;37:E1-E2.
25. Lai PH, Chen C, Liang HL, et al. Hyperintense basal ganglia on T1-weightedMR imaging. AJR Am J Roentgenol. 1999;172:1109-1115.
26. Kim TJ, Kim IO, Kim WS, et al. MR imaging of the brain in Wilson disease of childhood: findings before and after treatment with clinical correlation. AJNR Am J Neuroradiol. 2006;27:1373-1378.
27. Oikonomou A, Chatzistefanou A, Zezos P, et al. Basal ganglia hyperintensity on T1-weighted MRI in Rendu-Osler-Weber disease. J Magn Reson Imaging. 2012; 35:426-430.
28. Hernández MDCV, MacOnick LC, Tan EMJ, et al. Identification of mineral deposits in the brain on radiological images: a systematic review. Eur Radiol. 2012;22:2371-2381.
29. Shin YC, Kim E, Cheong HK, et al. High signal intensity on magnetic resonance imaging as a predictor of neurobehavioral performance of workers exposed to manganese. Neurotoxicology. 2007;28:257-262.
30. Mirowitz SA,Westrich TJ, Hirsch JD. Hyperintense basal ganglia on T1-weighted MR images in patients receiving parenteral nutrition. Radiology. 1991;181: 117-120.
31. Martin-Duverneuil N, Idbaih A, Hoang-Xuan K, et al. MRI features of neurodegenerative Langerhans cell histiocytosis. Eur Radiol. 2006;16:2074-2082.
32. Gathings RM, Reddy R, Cruz DS, et al. Gadolinium-associated plaques: a new, distinctive clinical entity. JAMA Dermatol. 2015;151:316-319.
33. Frenzel T, Lengsfeld P, Schirmer H, et al. Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37 degrees C. Invest Radiol. 2008;43:817-828.
34. Fretellier N, Idée J-M, Dencausse A, et al. Comparative in vivo dissociation of gadolinium chelates in renally impaired rats: a relaxometry study. Invest Radiol. 2011;46:292-300.
35. Steger-Hartmann T, Hofmeister R, Ernst R, et al. A review of preclinical safety data for Magnevist (gadopentetate dimeglumine) in the context of nephrogenic systemic fibrosis. Invest Radiol. 2010;45:520-528.
36. Kanda T, Osawa M, Oba H, et al. High signal intensity in dentate nucleus on unenhanced T1-weighted MR images: association with linear versus macrocyclic gadolinium chelate administration. Radiology. 2015;275:803-809.
37. RadbruchA,Weberling LD, Kieslich PJ, et al. Gadoliniumretention in the dentate nucleus and globus pallidus is dependent on the class of contrast agent. Radiology. 2015;275:783-791.
38. Cao Y, Huang DQ, Shih G, et al. Signal change in the dentate nucleus on T1-weighted MR images after multiple administrations of gadopentetate dimeglumine versus gadobutrol. AJR Am J Roentgenol. 2016;206:414-419.
39. Runge VM. Macrocyclic versus linear gadolinium chelates. Invest Radiol. 2015; 50:811.
40. Radbruch A,Weberling LD, Kieslich PJ, et al. High-signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted images: evaluation of the macrocyclic gadolinium-based contrast agent gadobutrol. Invest Radiol. 2015;50:805-810.
41. Zucca FA, Basso E, Cupaioli FA, et al. Neuromelanin of the human substantia nigra: an update. Neurotox Res. 2014;25:13-23.
42. Zecca L, Zucca F, Albertini A, et al. A proposed dual role of neuromelanin in the pathogenesis of Parkinson's disease. Neurology. 2006;67(7 suppl 2):S8-S11.
43. Rai AT, Hogg JP. Persistence of gadoliniumin CSF : a diagnostic pitfall in patients with end-stage renal disease. AJNR Am J Neuroradiol. 2001;22:1357-1361.
44. da Silva CJ, da Rocha AJ, Jeronymo S, et al. A preliminary study revealing a new association in patients undergoing maintenance hemodialysis: manganism symptoms and T1 hyperintense changes in the basal ganglia. AJNR Am J Neuroradiol. 2007;28:1474-1479.
45. Hegde AN, Mohan S, Lath N, et al. Differential diagnosis for bilateral abnormalities of the basal ganglia and thalamus. Radiographics. 2011;31:5-30.
46. Quattrocchi CC, Longo D, Delfino LN, et al. MR differential diagnosis of acute deep grey matter pathology in paediatric patients. Pediatr Radiol. 2013;43: 743-761.
47. Bruce R, Wentland AL, Haemel AK, et al. Incidence of nephrogenic systemic fibrosis using gadobenate dimeglumine in 1423 patients with renal insufficiency compared with gadodiamide. Invest Radiol. 2016. [Epub ahead of print].
48. Eovist [Package Insert]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc. 2015. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2015/022090s011lbl.pdf. Accessed March 29, 2016.
49. Ablavar [Package Insert]. North Billerica, MA: Lantheus Medical Imaging Inc. 2010. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2010/021711s003lbl.pdf. Accessed March 29, 2016.
50. Amet S, Launay-Vacher V, Clément O, et al. Incidence of nephrogenic systemic fibrosis in patients undergoing dialysis after contrast-enhanced magnetic resonance imaging with gadolinium-based contrast agents: the Prospective Fibrose Nephrogénique Systémique study. Invest Radiol. 2014;49:109-115.
51. Gadobutrol [Package Insert].Wayne, NJ: Bayer HealthCare Pharmaceuticals Inc 2013. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/201277s003lbl.pdf. Accessed March 29, 2016.
52. Endrikat J, Vogtlaender K, Dohanish S, et al. Safety of gadobutrol: results from42 clinical phase II to IV studies and postmarketing surveillance after 29 million applications. Invest Radiol. 2016. [Epub ahead of print].
53. Dotarem [Package Insert]. Bloomington, IN: Guerbet LLC. 2013. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/204781s000lbl.pdf. Accessed March 29, 2016.
54. Lauenstein T, Ramirez-Garrido F, Kim YH, et al. Nephrogenic systemic fibrosis risk after liver magnetic resonance imaging with gadoxetate disodium in patients with moderate to severe renal impairment: results of a prospective, open-label, multicenter study. Invest Radiol. 2015;50:416-422.
55. Prohance [Package Insert]. Monroe Township, NJ : Bracco Diagnositc Inc. 2013. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/020131s026,021489s003lbl.pdf. Accessed March 29, 2016.